510(k) device
Hyalomatrix
Anika Therapeutics, Inc. · Absorbable Synthetic Wound Dressing (QSZ, Unclassified) · First FDA decision Sep 2, 2026, newest Sep 2, 2026BurnsChronic wounds and ulcers
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
4
Naming "Hyalomatrix"
MAUDE reports
0
Brand "Hyalomatrix", since 2015
PubMed studies
30
Mentioning "Hyalomatrix"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Hyalomatrix
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- HYALOMATRIX510(k)
K261311 · Decided Sep 2, 2026 · 134 days after receipt
Device type: Absorbable Synthetic Wound Dressing (QSZ) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Hyalomatrix", any status and sponsor, newest update first.
- Evaluation of the Efficacy of Hyalomatrix® in the Healing of Chronic Venous Leg UlcersPivotal-lookingRecruiting
NuScience Medical Biologics, LLCNot on our public-company list
NCT07335861 · 122 participants (planned) · Start May 14, 2026 · Primary completion Dec 31, 2026
Device: Hyalomatrix · For: Venous Leg Ulcer; Chronic Wounds
Sites: Alexandria, Louisiana; Hammond, Louisiana; Lafayette, Louisiana · 12 sites in all
Gillette Children's Specialty HealthcareAcademic, hospital or other
NCT03107546 · 19 participants · Start May 11, 2017 · Primary completion Dec 31, 2022
Device: Hyalomatrix · For: Syndactyly
Sites: Saint Paul, Minnesota
Medline IndustriesNot on our public-company list
NCT02363543 · 0 participants · Start Feb 2016 · Primary completion May 2016
Device: Hyalomatrix; Integra · For: Bandages
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Hyalomatrix", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QSZ
86 reports: 7 malfunction, 79 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Hyalomatrix"[tiab]. The summary above synthesizes these.
- Foot Wounds and the Reconstructive Ladder.
Simman R, Abbas FT · Plast Reconstr Surg Glob Open · 2021
- Long-term in vivo assessment of bioengineered skin substitutes: a clinical study.
Nicoletti G, Brenta F, Bleve M, et al. · J Tissue Eng Regen Med · 2015Clinical Trial, Multicenter Study
- Hyalomatrix coverage in scalp wounds with exposed cranium and dura.
Kozusko SD, Bird D, Fahey AL · J Wound Care · 2023
- Interaction between a regenerative matrix and wound bed in nonhealing ulcers: results with 16 cases.
Motolese A, Vignati F, Brambilla R, et al. · Biomed Res Int · 2013Clinical Trial
- Skin cancers and dermal substitutes: Is it safe? Review of the literature and presentation of a 2-stage surgical protocol for the treatment of non-melanoma skin cancers of the head in fragile patients.
Marcasciano M, Mazzocchi M, Kaciulyte J, et al. · Int Wound J · 2018Case Reports, Review
- Versatile use of dermal substitutes: A retrospective survey of 127 consecutive cases.
Nicoletti G, Tresoldi MM, Malovini A, et al. · Indian J Plast Surg · 2018
- Hyalomatrix PA in burn care practice: results from a national retrospective survey, 2005 to 2006.
Gravante G, Sorge R, Merone A, et al. · Ann Plast Surg · 2010
- [Hyalomatrix PA(®) in skin substitutes. About 10 cases].
Perrot P, Dellière V, Brancati A, et al. · Ann Chir Plast Esthet · 2011English Abstract
- Hyalomatrix: a temporary epidermal barrier, hyaluronan delivery, and neodermis induction system for keratinocyte stem cell therapy.
Myers SR, Partha VN, Soranzo C, et al. · Tissue Eng · 2007Research Support, Non-U.S. Gov't
- The use of hyalomatrix PA in the treatment of extravasation affecting premature neonates.
Onesti MG, Carella S, Maruccia M, et al. · Plast Reconstr Surg · 2012Editorial
- The use of Hyalomatrix PA in the treatment of deep partial-thickness burns.
Gravante G, Delogu D, Giordan N, et al. · J Burn Care Res · 2007
- Surgical treatment of nasal non-melanoma skin cancer in elderly patients using dermal substitute.
Dessy LA, Marcasciano M, Fanelli B, et al. · Acta Otolaryngol · 2016Observational Study
Other devices of this type
Also filed under product code QSZ.
- RestrataAcera Surgical, Inc. · 510(k) 2026
- SiOxD® Wound MatrixSioxmed, LLC · 510(k) 2024
- NovoSorb BTMPolynovo Biomaterials Pty, Ltd. · 510(k) 2025
- LUOFUCON® Wound MatrixHuizhou Foryou Medical Devices Co., Ltd. · 510(k) 2026
- Redermo Wound MatrixBeijing Kreate Medical Co., Ltd. · 510(k) 2026
- NovoSorb® MTXPolynovo Biomaterials Pty, Ltd. · 510(k) 2025
- Restrata® MiniMatrixAcera Surgical, Inc. · 510(k) 2023
- NovoSorb MatrixPolynovo Biomaterials Pty, Ltd. · 510(k) 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.